Molecular-Genetic Aspects of Breast Cancer

1. Ahn, J. Y. et al. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. - Cancer Res., 60, 2000, № 21, 5934-5936.Search in Google Scholar

2. Ai, L. et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. - Cancer Epidemiol. Biomarkers Prev., 13, 2004, № 1, 150-156.10.1158/1055-9965.EPI-082-3Search in Google Scholar

3. Albain, K. S. et al. HER2 overexpression in Breast Cancer. - Genetech Inc., 1998.Search in Google Scholar

4. Allinen, M. et al. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. - Br. J. Cancer, 85, 2001, № 2, 209-212.10.1054/bjoc.2001.1858Search in Google Scholar

5. Almond, N. et V. Rotter. Involvement of p53 in cell differentiation and development. - Biochim. Biophys. Acta /Reviews on Cancer, 1333, 1997, № 1, 1-27.10.1016/S0304-419X(97)00012-7Search in Google Scholar

6. Angele, S. et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. - Clin. Cancer Res., 6, 2000, 3536-3544.Search in Google Scholar

7. Angelova, S. G. et al. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients. - Neoplasma, 59, 2012, № 6, 622-630.10.4149/neo_2012_07922862163Search in Google Scholar

8. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286, 1999, № 5449, 2528-2531.10.1126/science.286.5449.252810617473Search in Google Scholar

9. Bernstein, J. L. et al. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. - Br. J. Cancer, 89, 2003, 1513-1516.10.1038/sj.bjc.6601289239432814562025Search in Google Scholar

10. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. - Int. J. Cancer, 116, 2005, № 2, 263-266.10.1002/ijc.2102215810020Search in Google Scholar

11. Børresen, A. L. et al. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. - Genes Chromosomes Cancer, 2, 1990, № 4, 339-340.10.1002/gcc.28700204122268581Search in Google Scholar

12. Bozhanov, S. / Angelova S. et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. -J. Cancer Res. Clin. Oncol., 136, 2010, 1657-1669.10.1007/s00432-010-0824-920177704Search in Google Scholar

13. Brose, M. S. et al. Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program. - J. Natl. Cancer Inst., 94, 2002, 1365-1372.10.1093/jnci/94.18.136512237282Search in Google Scholar

14. Cable, P. L. et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. - Mol. Carcinog., 38, 2003, № 2, 85-96.10.1002/mc.10148Search in Google Scholar

15. Campbell, l. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. - Cancer Res., 64, 2004, 7678-7681.10.1158/0008-5472.CAN-04-2933Search in Google Scholar

16. Carr, J. A. et al. The association of HER-2/neu ampliffication with breast cancer recurrence. - Arch. Surg., 135, 2000, 1469-1474.10.1001/archsurg.135.12.1469Search in Google Scholar

17. Chen, S. et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. - J. Clin. Oncol., 24, 2006, № 6, 863-871.10.1200/JCO.2005.03.6772Search in Google Scholar

18. Cybulski, C. et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. - Breast Cancer Res. Treat., 102, 2007, № 1, 119-122.10.1007/s10549-006-9320-ySearch in Google Scholar

19. de Jong, M. M. et al. Genes other than BRCA1and BRCA2 involved in breast cancer susceptibility. - J. Med. Genet., 39, 2002, 225-242.10.1136/jmg.39.4.225Search in Google Scholar

20. Dobrovic, A. et D. Simpfendorfer. Methylation of the BRCA1 Gene in Sporadic Breast Cancer. - Cancer Res., 57, 1997, 3347-3350.Search in Google Scholar

21. Honrado, E. et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. - Oncogene, 25, 2006, № 43, 5837-5845.10.1038/sj.onc.1209875Search in Google Scholar

22. Iannuzzi, C. M. et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. - Int. J. Radiat. Oncol. Biol. Phys., 52, 2002, № 3, 606-613.10.1016/S0360-3016(01)02684-0Search in Google Scholar

23. Kastan, M. B. et J. Bartek. Cell-cycle checkpoints and cancer. - Nature, 432, 2004, № 7015, 316-323.10.1038/nature0309715549093Search in Google Scholar

24. Kilinc, N. et M. Yaldiz. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters. - Eur. J. Gynaecol. Oncol., 25, 2004, 5, 606-610.Search in Google Scholar

25. Kilpivaara, O. et al. CHEK2 variant I157T may be associated with increased breast cancer risk. - Int. J. Cancer, 111, 2004, 543-547.10.1002/ijc.2029915239132Search in Google Scholar

26. Krasteva, M. E. et al. Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status. - Neoplasma, 59, 2012, № 1, 85-91.10.4149/neo_2012_011Search in Google Scholar

27. Krasteva, M. et al. Aberrant promoter methylation in p53 and ATM genes was not associated with sporadic breast carcinogenesis in Bulgarian patients. - J. BioSci. Biotech., 3, 2014, № 2, 105-109.Search in Google Scholar

28. Lacroix, M., R. A. Toillon et G. Leclercq. P53 and breast cancer, an update. - Endocr. Relat. Cancer, 13, 2006, № 2, 293-325.10.1677/erc.1.01172Search in Google Scholar

29. Lavin, M. F. et S. Kozlov. ATM activation and DNA damage response. - Cell Cycle, 6, 2007, № 8, 931-942.10.4161/cc.6.8.4180Search in Google Scholar

30. Lavin, M. F. The Mre11 complex and ATM: a two-way functional interaction in recognising and signaling DNA double strand breaks. - DNA Repair (Amst), 3, 2004, № 11, 1515-1520.10.1016/j.dnarep.2004.07.001Search in Google Scholar

31. Lawler, J. et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53- deficient mice. - Am. J. Pathol., 159, 2001, 1949-1956.10.1016/S0002-9440(10)63042-8Search in Google Scholar

32. Li, S. et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. - Nature, 406, 2000, № 6792, 210-215.10.1038/3501813410910365Search in Google Scholar

33. Lukas, C. et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. - Cancer Res., 61, 2001, № 13, 4990-4993.Search in Google Scholar

34. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. - Science, 250, 1990, № 4985, 1233-1238.10.1126/science.19787571978757Search in Google Scholar

35. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. - Proc. Natl. Acad. Sci. U S A, 97, 2000, № 19, 10389-10394.10.1073/pnas.1900304972703410973490Search in Google Scholar

36. Meijers-HeIjboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. - Nat. Genet., 31, 2002, № 1, 55-59.10.1038/ng87911967536Search in Google Scholar

37. Muthuswamy, S. K. et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. - Nat. Cell Biol., 3, 2001, 785-792.10.1038/ncb0901-785295254711533657Search in Google Scholar

38. Offterdinger, M., S. M. Schneider et T. W. Grunt. Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels. - J. Cell Physiol., 195, 2003, 260-275.10.1002/jcp.10237Search in Google Scholar

39. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. - Hum. Mutat., 19, 2002, 607-614.10.1002/humu.10081Search in Google Scholar

40. O’ DrIscoll M. et P. A. Jeggo. The role of double-strand break repair - insights from human genetics. - Nat. Rev. Genet., 7, 2006, № 1, 45-54.10.1038/nrg1746Search in Google Scholar

41. Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. - J. Natl. Cancer Inst., 91, 1999, № 11, 943-949.10.1093/jnci/91.11.943Search in Google Scholar

42. Pharoah, P. D., N. E. Day et C. Caldas. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. - Br. J. Cancer, 80, 1999, 1968-1973.10.1038/sj.bjc.6690628Search in Google Scholar

43. Rice, J. C., K. S. Massey-Brown et B. W. Futscher. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. - Oncogene, 17, 1998, 1807-1812.10.1038/sj.onc.1202086Search in Google Scholar

44. Ross, J. S. et al. The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy. - Oncologist, 8, 2003, 307-325.10.1634/theoncologist.8-4-307Search in Google Scholar

45. Rudolph, P. et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. - J. Pathol., 187, 1999, 207-216.10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-USearch in Google Scholar

46. Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. - Cancer Res., 65, 2005, 2554-2559.10.1158/0008-5472-CAN-04-3913Search in Google Scholar

47. Sansal, I. et W. R. Sellers. The biology and clinical relevance of the PTEN tumor suppressor pathway. - J. Clin. Oncol., 22, 2004, 2954-2963.10.1200/JCO.2004.02.141Search in Google Scholar

48. Seo, Y. R. et H. J. Jung. The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). - Exp. Mol. Med., 36, 2004, № 60, 505-509.10.1038/emm.2004.6415665582Search in Google Scholar

49. Shaag, A. et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. - Hum. Mol. Genet., 14, 2005, № 4, 555-563.10.1093/hmg/ddi05215649950Search in Google Scholar

50. Singh, B. et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. - Genes Dev., 16, 2002, 984-993.10.1101/gad.97360215235411959846Search in Google Scholar

51. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. - Science, 235, 1987, 177-182.10.1126/science.37981063798106Search in Google Scholar

52. Sodha, N. et al. Screening hCHK2 for mutations. - Science, 289, 2000, № 5478, 359.10.1126/science.289.5478.359a10939935Search in Google Scholar

53. Stoppa - Lyonnet, D. et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. - J. Clin. Oncol., 18, 2000, 4053-4059.10.1200/JCO.2000.18.24.405311118466Search in Google Scholar

54. Tuma, R. S. Trastuzumab trials steal show at ASCO meeting. - J. Natl. Cancer Inst., 97, 2005, 870-871.10.1093/jnci/97.12.87015956644Search in Google Scholar

55. Turner, N., A. Tutt et A. Ashworth. Hallmarks of ‚BRCAness‘ in sporadic cancers. - Nature Reviews of Cancer, 4, 2004, 814-819.10.1038/nrc145715510162Search in Google Scholar

56. Weischer, M. et al. Increased risk of breast cancer associated with CHEK2*1100delC. - J. Clin. Oncol., 25, 2007, № 1, 57-63.10.1200/JCO.2005.05.516016880452Search in Google Scholar

57. Wong, M. W. et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. - Breast Cancer Res. Treat., 127, 2011, № 3, 853-859.10.1007/s10549-011-1443-021409391Search in Google Scholar

58. Xu, X., L. M. Tsvetkov et D. F. Stern. Chk2 activation and phosphorylation-dependent oligomerization. - Mol. Cell Biol., 22, 2002, № 12, 4419-4432. 10.1128/MCB.22.12.4419-4432.200213385812024051Search in Google Scholar